Equities

Synektik SA

Synektik SA

Actions
Health CareHealth Care Providers
  • Price (PLN)147.00
  • Today's Change4.40 / 3.09%
  • Shares traded22.99k
  • 1 Year change+108.81%
  • Beta--
Data delayed at least 15 minutes, as of Jul 03 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Synektik SA is a Poland-based company active in the medical sector. It produces PACS software which allows running a diagnostic imaging laboratory. It runs a research laboratory which performs acceptance and specialist tests of X-ray equipment. The Company sells medical equipment and operates a services center for imaging equipment. Synektik SA is a partner of Siemens. On November 28, 2013, the Company raised its stake in Miedzynarodowe Centra Medyczne Inwestycje Sp z o o to 100%.

  • Revenue in PLN (TTM)596.39m
  • Net income in PLN76.24m
  • Incorporated2011
  • Employees164.00
  • Location
    Synektik SAul. Jozefa Piusa Dziekonskiego 3WARSZAWA 00-728PolandPOL
  • Phone+48 223270900
  • Fax+48 228498055
  • Websitehttps://www.synektik.com.pl/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Agfa Gevaert NV4.87bn-206.86m749.93m5.03k--0.4579--0.154-0.315-0.36187.372.450.73932.314.61224,830.90-3.21-4.24-5.02-6.2230.7129.49-4.34-5.601.15--0.2107--0.4367-12.1071.20---3.20--
Prim SA933.05m54.61m756.22m900.0013.831.397.730.81050.7450.74512.737.401.121.994.10240,567.406.586.689.248.9037.9338.115.856.431.22--0.168159.389.7710.0051.02-2.1412.86-5.01
Onward Medical NV0.00-155.92m764.07m99.00--8.62-----1.20-1.200.000.5940.00----0.00-60.19-55.70-68.71-61.60-------79,513.95---58.040.4848---34.62---10.40--32.59--
Bactiguard Holding AB83.70m-47.83m826.11m191.00--7.16--9.87-3.60-3.606.309.800.30354.286.001,017,544.00-17.35-7.56-19.82-8.8129.8747.91-57.15-26.281.64-11.900.4129---11.966.46-161.71--8.43--
Sedana Medical AB (publ)62.51m-8.66m858.56m83.00--2.2933,307.1013.73-0.2299-0.22991.669.950.15641.248.102,087,443.00-2.17-5.77-2.28-6.0870.5064.06-13.85-36.137.38--0.0043--25.2321.5918.90--42.12--
Nyxoah SA22.10m-186.20m995.07m147.00--2.21--45.03-1.51-1.510.17893.040.03890.82972.2934,931.88-32.74-23.73-36.67-25.9862.2562.42-842.59-1,469.593.70--0.1275--40.99---38.39--100.58--
Lumibird SA877.24m30.71m1.09bn1.05k31.611.3110.331.240.35590.35599.148.620.52381.094.05193,497.101.833.132.443.9961.6861.763.505.891.622.470.42870.006.6015.12-37.23-2.4718.34--
BICO Group AB856.52m-609.28m1.16bn837.00--1.03--1.36-22.34-26.3931.7342.970.33982.334.142,555,996.00-24.19---27.59--50.48---71.20--1.95-13.810.3933--6.09---1,889.33------
Medistim ASA199.51m38.53m1.16bn152.0030.167.2024.455.845.605.6029.0123.481.030.77656.153,492,704.0019.9522.9324.0728.5279.0278.2519.3120.642.99--0.020675.257.0010.06-8.9112.720.03314.87
Detection Technology Oyj-430.95bn-430.95bn1.18bn478.00--3.75----------4.97----------9.34--11.96--47.44--8.223.13--0.08153.455.292.027.55-18.03-14.88-9.55
Synektik SA596.39m76.24m1.22bn164.0015.957.8814.252.048.948.9469.9218.102.1214.619.113,897,992.0027.0910.2444.2815.7926.3822.8612.788.851.1713.770.102447.00167.81--409.18------
COLTENE Holding AG1.08bn53.01m1.23bn1.20k23.232.8714.781.142.002.0040.6216.211.331.406.58201,937.606.5310.4810.9018.7464.2462.684.927.470.80455.620.317279.94-9.133.54-54.05-6.81-7.72-7.79
IVF Hartmann Holding AG656.45m67.21m1.34bn304.0019.972.0014.632.046.316.3161.6363.070.80153.088.46486,687.508.217.299.998.9053.9053.2910.248.303.89--0.005652.16-1.792.0934.951.49-14.8326.82
RaySearch Laboratories AB (publ)397.72m38.18m1.45bn398.0048.806.339.763.642.942.9430.6422.650.53135.652.972,697,136.005.101.297.801.8889.9290.579.602.551.1947.170.403669.0021.1610.26243.060.7648-1.31--
Ion Beam Applications SA1.85bn-39.26m1.59bn1.99k--3.35153.230.8617-0.3139-0.313914.723.640.7022.542.65215,869.60-1.491.55-5.924.3231.3635.23-2.122.380.71031.400.281464.8318.6710.74-250.40---8.06--
Data as of Jul 03 2024. Currency figures normalised to Synektik SA's reporting currency: Polish New Zloty PLN

Institutional shareholders

7.99%Per cent of shares held by top holders
HolderShares% Held
Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SAas of 31 Dec 2023301.31k3.53%
Generali PTE SAas of 29 Dec 2023173.55k2.04%
Norges Bank Investment Managementas of 31 Dec 2023147.76k1.73%
Dimensional Fund Advisors LPas of 06 Jun 202444.31k0.52%
Rockbridge TFIas of 30 Jun 20234.51k0.05%
Acadian Asset Management LLCas of 31 Mar 20244.04k0.05%
Alphajet Fair Investors SASas of 25 Jun 20243.50k0.04%
DFA Australia Ltd.as of 31 May 20241.39k0.02%
Andbank Wealth Management SGIIC SAUas of 31 Dec 20231.39k0.02%
Lingohr Asset Management GmbHas of 30 Apr 20240.000.00%
More ▼
Data from 29 Dec 2023 - 25 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.